NRAS and melanoma: Some scientists have struggled to find drugs targeting the mutated NRAS protein or NRAS protein [19], while others have uncovered a mechanism of resistance of targeted therapies for melanoma and identified compounds that inhibit eIF4F and enhance the effectiveness of vemurafenib in mice with melanomas [20].